Valuation: Vista Pharmaceuticals Limited

Market Cap 376M 3.95M 3.43M 3.21M 2.93M 5.54M 5.61M 37.53M 14.73M 188M 14.82M 14.5M 625M P/E 2024
-10.3x
P/E 2025 -13.6x
Enterprise Value 443M 4.65M 4.03M 3.78M 3.46M 6.52M 6.61M 44.19M 17.34M 221M 17.45M 17.07M 736M EV / Sales 2024
7.63x
EV / Sales 2025 8.85x
Free-Float
22.51%
Yield 2024 *
-
Yield 2025 -
02-13 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
02-03 Vista Pharmaceuticals enters joint venture with Pleiades Therapeutics RE
13/08/25 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
16/07/25 Vista Pharmaceuticals Limited announced that it has received INR 30.749994 million in funding CI
30/05/25 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
19/02/25 Vista Pharmaceuticals Limited announced that it expects to receive INR 146.614482 million in funding CI
12/02/25 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
13/11/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
13/08/24 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
28/05/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
10/02/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
08/01/24 Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding CI
10/11/23 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
1 day+2.07%
1 week+6.16%
Current month+3.92%
1 month-6.00%
3 months-13.66%
6 months-15.04%
Current year-15.36%
1 week 6.1
Extreme 6.1
7
1 month 6.1
Extreme 6.1
7.77
Current year 5.71
Extreme 5.71
8.87
1 year 5.71
Extreme 5.71
11.45
3 years 5.71
Extreme 5.71
19.7
5 years 5.71
Extreme 5.71
19.7
10 years 4.51
Extreme 4.51
56.15
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Compliance Officer - 10/02/2024
Director TitleAgeSince
Chairman 76 02/01/2014
Director/Board Member 87 16/06/1993
Director/Board Member 76 02/02/2010
Change 5-day change 1-year change 3-year change Capi.($)
+2.07%+6.16%-34.69%-30.82% 4.37M
+0.57%-1.95%+19.54%+71.30% 48.95B
+3.09%+5.78%+64.08%+134.31% 39.36B
+1.25%+0.18%-1.52%+22.09% 12.39B
-1.17%-1.31%+15.39%+70.53% 11.76B
+1.53%-0.38%+30.75%+134.53% 9.14B
-0.25%+3.25%+15.49%+35.50% 7.05B
+1.61%-6.16%+38.63%-12.74% 6.86B
+0.49%+0.37%+10.59%+182.50% 6.7B
-1.46%+2.33%-30.59%+14.13% 5.67B
Average +0.77%-0.02%+12.77%+62.13% 14.79B
Weighted average by Cap. +1.15%-0.40%+28.35%+85.03%

Financials

2024 2025
Net sales 103M 1.08M 937K 878K 803K 1.52M 1.54M 10.27M 4.03M 51.4M 4.05M 3.97M 171M 101M 1.06M 918K 859K 786K 1.48M 1.5M 10.05M 3.95M 50.34M 3.97M 3.88M 168M
Net income -45.12M -474K -411K -385K -352K -665K -673K -4.5M -1.77M -22.54M -1.78M -1.74M -75.03M -46.49M -488K -423K -397K -363K -685K -694K -4.64M -1.82M -23.23M -1.83M -1.79M -77.31M
Net Debt 78.7M 826K 717K 671K 614K 1.16M 1.17M 7.85M 3.08M 39.32M 3.1M 3.03M 131M 66.71M 700K 608K 569K 521K 983K 996K 6.66M 2.61M 33.33M 2.63M 2.57M 111M
Logo Vista Pharmaceuticals Limited
Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
Employees
30
Date Price Change Volume
06/08/26 6.890 +2.07% 6,568
05/08/26 ₹6.750 +1.50% 5,851
04/08/26 ₹6.650 +1.22% 2,465
03/08/26 ₹6.570 -0.90% 4,586
31/07/26 ₹6.630 +0.91% 12,291
  1. Stock Market
  2. Stocks
  3. VISTAPH6 Stock